SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-23
👔
Outlook Therapeutics, Inc.
@OTLK_InsiderForm 4 Filing: Jahr Robert Charles Acquires (Grant) shares of $OTLK
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
Outlook Therapeutics, Inc.
Ticker: $OTLK
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-07-21
Shares: 100,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Jahr Robert Charles, holds the title of Chief Executive Officer at Outlook Therapeutics, Inc..
On 2026-07-21, the insider transacted 100,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Jahr Robert Charles (Chief Executive Officer) was granted $0 of $OTLK
Post-Transaction Position: 100,000 shares
SEC Accession No: 0001649989-26-000006 (CIK: 2076177)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.